Vagus nerve stimulation for drug-resistant epilepsy

Area of Science:

• Neurology
• Neurosurgery
• Medical Devices

Background:

• Epilepsy affects millions globally, with a significant portion experiencing drug-resistant forms.
• Vagus nerve stimulation (VNS) offers a neuromodulatory approach for managing refractory epilepsy.
• Current treatment paradigms for drug-resistant epilepsy are limited, necessitating alternative therapeutic strategies.

Purpose of the Study:

• To review the efficacy of VNS in reducing seizure frequency in drug-resistant epilepsy.
• To evaluate the impact of VNS on patients' quality of life.
• To discuss practical management and adverse effects associated with VNS therapy.

Main Methods:

• Systematic review of randomized controlled trials and long-term uncontrolled studies on VNS for epilepsy.
• Analysis of seizure frequency reduction, quality of life metrics, and adverse event profiles.
• Inclusion of clinical guidance for patient management with VNS.

Main Results:

• VNS implantation achieves >50% seizure frequency reduction in 26%-40% of patients within one year.
• Long-term studies indicate that VNS efficacy may improve over time.
• Evidence supports VNS for focal seizures and other epilepsy types, though predictive factors remain debated.

Conclusions:

• Vagus nerve stimulation is a valuable therapeutic option for drug-resistant epilepsy, improving seizure control and quality of life.
• While effective, careful patient selection and management are crucial for optimizing VNS outcomes.
• Further research may clarify predictive factors for VNS response and expand its therapeutic applications.